- |||||||||| Venclexta (venetoclax) / Roche, AbbVie
High Response and Prolonged Treatment-Free Remission after a Short-Course of Modified Intensive Chemotherapy and Venetoclax in Elderly AML: An Updated Analysis of the Caveat Trial (ENMCC - 275-277) - Nov 4, 2022 - Abstract #ASH2022ASH_5058; Background Venetoclax (VEN) plus azacitidine has an established role in the management of older patients (pts) with AML (DiNardo, NEJM 2020)...We now present an updated analysis of this trial (with >3 years median follow-up), reporting on the optimal dose of VEN with chemotherapy, with and without posaconazole (POSA), the deliverability of consolidation therapy, characteristics of treatment failure and observation of substantial treatment-free remission in subsets of pts using this time-limited, short-course regimen...For induction, VEN was administered over 14 days, commencing with a 7-day pre-chemo dose ramp-up, followed by a 7-day overlap with 5+2 chemotherapy (cytarabine 100mg/m2/d IVI d1-5 and idarubicin 12mg/m2 IV d2-3)...Induction with VEN-POSA (n=18) was also well tolerated (30-day mortality 0%) with 3 DLTs observed: 2 hematologic (1 in each cohort) and 1 due to pulmonary infiltrates occurring on d2 induction (suspected to be allopurinol hypersensitivity)...With long-term follow-up, the time-limited CAVEAT schedule enabled pts, especially with mutated NPM1 or IDH2, to experience a durable treatment-free remission. Cumulative hematological toxicity is limiting, prompting us to now explore non-anthracycline CONS (low dose cytarabine 20mg/m2 SC d1-10 + VEN 400mg d1-7, for up to 4 cycles), followed by VEN monotherapy (400mg D1-14 q28d cycle x7).
- |||||||||| colchicine / Generic mfg.
Journal: Colchicine use and the risk of CKD progression: A multicenter nested case-control study. (Pubmed Central) - Nov 4, 2022 The results of the Mann Whitney test showed that there was a significant difference in the levels of N7-CAG between the test group and the negative control group with p value less than 0.001. Colchicine use is associated with a lower risk of adverse kidney outcomes in CKD patients with hyperuricaemia, or chronic gout.
- |||||||||| allopurinol / Generic mfg.
Preclinical, Journal: Computer-assisted in vitro Reconstitution of Purine Degradation Pathway to Lower the Purine Content in Food. (Pubmed Central) - Nov 4, 2022 Colchicine use is associated with a lower risk of adverse kidney outcomes in CKD patients with hyperuricaemia, or chronic gout. This is the first in vitro reconstitution of complete purine metabolic pathway by combining ANN and GA technologies, with successful application with respect to lowering the purine content in food, indicating a promising application of computer-assisted in vitro reconstitution of purinolytic pathway in low-purine food to prevent hyperuricemia and gout.
- |||||||||| Trial suspension: Allo HSCT Using RIC for Hematological Diseases (clinicaltrials.gov) - Nov 4, 2022
P2, N=124, Suspended, These findings provide a scientific basis for the application of catechins in dietary supplements and medicines with lowering uric acid effects. Recruiting --> Suspended
- |||||||||| Lonquex (lipegfilgrastim biosimilar) / Teva
Journal: Lipegfilgrastim may cause hyperleukocytosis. (Pubmed Central) - Nov 2, 2022 Recruiting --> Suspended Although lipegfilgrastim-induced hyperleukocytosis has not been reported in the literature, it should be borne in mind that hyperleukocytosis and related complications may occur, as in our case.
- |||||||||| Drug-induced Hepatotoxicity - many Rheum drugs on the list: Tylenol, azathioprine, allopurinol, cyclosporine, dapsone, gold, MTX, 6-MP, NSAIDs, ASA, SSZ, Minocin... https://t.co/wuoVrDgesq (Twitter) - Nov 2, 2022
- |||||||||| allopurinol / Generic mfg.
Trial completion date, Trial primary completion date, Combination therapy: Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial) (clinicaltrials.gov) - Oct 28, 2022 P1/2, N=30, Not yet recruiting, Only a minor improvement in persistence was seen, and a moderate increase in compliance with guidelines, suggesting a need for improved management and extended patient involvement to increase and optimize the use of urate lowering therapy. Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jan 2024 --> Jun 2024
- |||||||||| allopurinol / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid (clinicaltrials.gov) - Oct 26, 2022 P2, N=34, Completed, Further study into culprit drug distribution by region as well as continuous monitoring of trends is crucial in order to advise prescribing practices. Recruiting --> Completed | N=140 --> 34 | Trial completion date: Sep 2022 --> Mar 2022 | Trial primary completion date: Sep 2022 --> Mar 2022
- |||||||||| allopurinol / Generic mfg.
Journal: Chronic diarrhea secondary to canine leishmaniosis: Case series. (Pubmed Central) - Oct 25, 2022 All dogs treated had a complete resolution of diarrhea with specific treatment for leishmaniosis alone, based on meglumine antimoniate (75-100 mg/kg SID SC for 1 month) plus allopurinol (10 mg/kg BID PO ≥ 6 months). This study suggests that leishmaniosis should be also included in the differential diagnosis of dogs from endemic areas presenting with the primary problem of large-bowel, small-bowel, or mixed-bowel chronic diarrhea.
- |||||||||| febuxostat / Generic mfg., allopurinol / Generic mfg.
Journal: Comparison of Febuxostat and Allopurinol in the Treatment of Patients with Chronic Kidney Disease Stage 3∼5 with Hyperuricemia. (Pubmed Central) - Oct 22, 2022 The total effective rate of the experimental group and the control group was 82.00% and 78.00%, respectively, with little difference (P > 0.05); compared with before treatment, BUN, Scr, and UA of the two groups were decreased (P < 0.05); and the degree of decline in the experimental group was significantly greater than that in the control group (P < 0.05); the incidence of adverse reactions in the control group was 22.00%, which was significantly higher than that in the experimental group (10.00%) (P < 0.05). Compared with allopurinol, febuxostat can improve renal function, reduce UA levels, and reduce the occurrence of complications, with high safety, which is worthy of further clinical promotion.
- |||||||||| allopurinol / Generic mfg.
Journal: Predictors of Patient and Physician Assessments of Gout Control. (Pubmed Central) - Oct 21, 2022 For both patients and physicians, absence of gout flares and serum urate levels at the treatment target predict assessment of gout control. However, discordance between patients and physicians in their assessment of disease control is not uncommon, with recent gout flares and tophus predicting lower scores by physicians than patients.
- |||||||||| Uriadec (topiroxostat) / Fuji Yakuhin, Medca Japan
Review, Journal: Chronic kidney disease: which role for xanthine oxidoreductase activity and products? (Pubmed Central) - Oct 18, 2022 Moreover, CKD is common in patients with gout, which is characterized by hyperuricemia, and in patients with cardiovascular diseases, which are associated with hypertension, endothelial dysfunction and atherosclerosis. Although hyperuricemia is undoubtedly related to CKD, controversial findings have been hitherto reported in patients treated with urate-lowering therapies.
- |||||||||| febuxostat / Generic mfg., allopurinol / Generic mfg.
Retrospective data, Review: Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis. (Pubmed Central) - Oct 18, 2022 However, in patients with a history of cardiovascular disease, allopurinol treatment is associated with less cardiovascular mortality as compared with febuxostat. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/#loginpage, identifier PROSPERO, CRD42022325656.
- |||||||||| allopurinol / Generic mfg.
Allopurinol-induced DRESS syndrome associated to HLA-B*58:01 () - Oct 17, 2022 - Abstract #EUSEM2022EUSEM_1329; Corticosteroid treatment was completed with blood test control and abdominal ultrasound that confirmed resolution of both liver and skin involvement at discharge.A few weeks after discharge from hospital, the patient worsened, requiring treatment with daily prednisone, which was escalated to intravenous immunoglobulins, and due to the persistence of symptoms, treatment with plasmapheresis has been recently started.From this case we can learn the importance of an acute differential diagnosis without underestimating the iatrogenic nature of adverse reactions associated with drugs, as well as the importance of anticipating situations that can endanger the patient's life. Specifically in this case, recalling the clinical course of DRESS syndrome, and considering other possible diagnoses as well as other potentially lethal drug skin reactions such as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis.As a learning, it also includes a complete multidisciplinary study that began in the emergency room and was completed during hospitalization and outpatient follow-up by various specialists.
- |||||||||| allopurinol / Generic mfg.
Allopurinol-induced DRESS syndrome associated to HLA-B*58:01 () - Oct 17, 2022 - Abstract #EUSEM2022EUSEM_1328; Corticosteroid treatment was completed with blood test control and abdominal ultrasound that confirmed resolution of both liver and skin involvement at discharge.A few weeks after discharge from hospital, the patient worsened, requiring treatment with daily prednisone, which was escalated to intravenous immunoglobulins, and due to the persistence of symptoms, treatment with plasmapheresis has been recently started.From this case we can learn the importance of an acute differential diagnosis without underestimating the iatrogenic nature of adverse reactions associated with drugs, as well as the importance of anticipating situations that can endanger the patient's life. Specifically in this case, recalling the clinical course of DRESS syndrome, and considering other possible diagnoses as well as other potentially lethal drug skin reactions such as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis.As a learning, it also includes a complete multidisciplinary study that began in the emergency room and was completed during hospitalization and outpatient follow-up by various specialists.
- |||||||||| allopurinol / Generic mfg.
Allopurinol-induced DRESS syndrome associated to HLA-B*58:01 () - Oct 17, 2022 - Abstract #EUSEM2022EUSEM_1327; Corticosteroid treatment was completed with blood test control and abdominal ultrasound that confirmed resolution of both liver and skin involvement at discharge.A few weeks after discharge from hospital, the patient worsened, requiring treatment with daily prednisone, which was escalated to intravenous immunoglobulins, and due to the persistence of symptoms, treatment with plasmapheresis has been recently started.From this case we can learn the importance of an acute differential diagnosis without underestimating the iatrogenic nature of adverse reactions associated with drugs, as well as the importance of anticipating situations that can endanger the patient's life. Specifically in this case, recalling the clinical course of DRESS syndrome, and considering other possible diagnoses as well as other potentially lethal drug skin reactions such as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis.As a learning, it also includes a complete multidisciplinary study that began in the emergency room and was completed during hospitalization and outpatient follow-up by various specialists.
- |||||||||| allopurinol / Generic mfg.
Allopurinol-induced DRESS syndrome associated to HLA-B*58:01 () - Oct 17, 2022 - Abstract #EUSEM2022EUSEM_1326; Corticosteroid treatment was completed with blood test control and abdominal ultrasound that confirmed resolution of both liver and skin involvement at discharge.A few weeks after discharge from hospital, the patient worsened, requiring treatment with daily prednisone, which was escalated to intravenous immunoglobulins, and due to the persistence of symptoms, treatment with plasmapheresis has been recently started.From this case we can learn the importance of an acute differential diagnosis without underestimating the iatrogenic nature of adverse reactions associated with drugs, as well as the importance of anticipating situations that can endanger the patient's life. Specifically in this case, recalling the clinical course of DRESS syndrome, and considering other possible diagnoses as well as other potentially lethal drug skin reactions such as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis.As a learning, it also includes a complete multidisciplinary study that began in the emergency room and was completed during hospitalization and outpatient follow-up by various specialists.
- |||||||||| allopurinol / Generic mfg.
Journal: Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. (Pubmed Central) - Oct 17, 2022 P4 Specifically in this case, recalling the clinical course of DRESS syndrome, and considering other possible diagnoses as well as other potentially lethal drug skin reactions such as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis.As a learning, it also includes a complete multidisciplinary study that began in the emergency room and was completed during hospitalization and outpatient follow-up by various specialists. In this large, randomised clinical trial in patients aged 60 years or older with ischaemic heart disease but no history of gout, there was no difference in the primary outcome of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death between participants randomised to allopurinol therapy and those randomised to usual care.
- |||||||||| febuxostat / Generic mfg., allopurinol / Generic mfg.
Efficacy and Safety of Urate Lowering Therapy (ULT) in CKD Patients With Gout (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_3292; Conclusion This prespecified sub-analysis from a large, RCT demonstrates that ALL and FEB are equally efficacious and well-tolerated in the treatment of gout in CKD when used in a treat-to-target regimen. Primary and secondary end points
- |||||||||| febuxostat / Generic mfg., allopurinol / Generic mfg.
UPLC-MS/MS-Based Plasma Assay for Therapeutic Monitoring in Patients With APRT Deficiency (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_2977; In patients receiving XOR inhibitor therapy, the median plasma concentration for allopurinol, oxypurinol and febuxostat was 687 (103-2901), 7945 (2199-10943) and 1628 ng/mL, respectively. Conclusion A UPLC-MS/MS assay for quantification of DHA, adenine, allopurinol, oxypurinol and febuxostat in human plasma was developed and optimized using DoE.
- |||||||||| colchicine / Generic mfg., allopurinol / Generic mfg.
Preclinical, Journal: Anti-inflammatory potential of stevia residue extract against uric acid-associated renal injury in mice. (Pubmed Central) - Oct 13, 2022 The polyphenolic compounds are abundantly present in plants, for example, stevia residue extract (STR) exert a positive effect on human health. From this study results, we can recommend that polyphenolic compounds enrich STR could be applied to develop treatment options for the treatment of hyperuricemia and gout.
- |||||||||| allopurinol / Generic mfg.
Preclinical, Journal: Shikonin derivatives as potent xanthine oxidase inhibitors: in-vitro study. (Pubmed Central) - Oct 11, 2022 Therefore, their iso-hexenylnaphthazarin nucleus was studied and found that the nucleus is similar to that of allopurinol, signifying the XO inhibitory potential of these derivatives...β,β-dimethylacrylshikonin and deoxyshikonin showed a good XO inhibition potential with IC values of 7.475 ± 1.46 µg/mL and 4.487 ± 0.88 µg/mL, respectively. Results also validated the pharmacophore hypothesis, and it was concluded that nucleus iso-hexenylnaphthazarin can be remodelled for optimising the efficacy.
- |||||||||| allopurinol / Generic mfg.
A Case Series of HLA-B*58:01 Specific Allopurinol-Induced DRESS/DIHS (Exhibit Hall (Upper Concourse); Monitor 02) - Oct 10, 2022 - Abstract #ACAAI2022ACAAI_845; Recent guidelines recommend screening for the HLA*58:01 allele in Southeast Asian and African patients prior to initiation of allopurinol. Our case series highlights the importance of recognizing populations with high HLA-B*58:01 allele frequency before introduction of allopurinol to prevent DRESS/DIHS.
|